CoChat

Development of Candidate Genomic Markers to Select Breast Cancer Patients for Dasatinib Therapy

Moulder, Stacy, Yan, Kai, Huang, Fei, Hess, Kenneth R., Liedtke, Cornelia, Lin, Feng, Hatzis, Christos, Hortobagyi, Gabriel N., Symmans, W. Fraser, Pusztai, Lajos · 2010 · Molecular Cancer Therapeutics
Cited by 33

The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.

Abstract

Patient selection is important for targeted therapies, yet phase I/II trials are often underpowered for developing predictors of drug response. The goal of this research was to define genomic predictors for dasatinib that could be prospectively tested in early-phase clinical trials. Gene expression profiles of dasatinib-sensitive and dasatinib-resistant cell lines (n = 23) were compared to develop a dasatinib-sensitivity index (modified DS index). A Src pathway activity index (revised Src index) was defined using genes induced by the Src transfection of mammary epithelial cells and was optimized to be reproducible across cell lines and human specimens. A dasatinib target index was devised using the weighted sum of 19 kinases that bind to dasatinib with variable affinity. The performance of these prediction models was assessed in independent cell lines with known dasatinib sensitivity. The feasibility of applying these genomic tests to human samples was evaluated on 133 biopsies of primary breast cancers. The modified DS index showed 90% accuracy in independent breast cancer cell lines (n = 12) and the target index, but not the revised Src index signature, also distinguished dasatinib-sensitive and dasatinib-resistant cells (P = 0.0024). The genomic predictors showed acceptable reproducibility in replicate cell line and human gene expression data. When all three predictors were applied to the same 133 patient samples, the predictors identified different patient subsets as potentially sensitive. We defined three conceptually different potential predictors of dasatinib response that were reproducible across cell lines and human data. These candidate markers are being tested in a clinical trial to determine their utility. Mol Cancer Ther; 9(5); 1120–7. ©2010 AACR.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1158/1535-7163.mct-09-1117

Cites

2 of 2 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 2 references

Cited by

See all 33

Metadata

Authors
Moulder, S., Yan, K., Huang, F., Hess, K. R., Liedtke, C., Lin, F., Hatzis, C., Hortobagyi, G. N., Symmans, W. F., & Pusztai, L.
Venue
Molecular Cancer Therapeutics
Published
2010-05-01
Volume
9
Issue
5
Pages
1120-1127
ISSN
  • 1535-7163 (ISSN-L)
  • 1538-8514
OpenAlex
W2105336633
Cited by
33
References
2
FWCI
1.90
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Development of Candidate Genomic Markers to Select Breast Cancer Patients for Dasatinib Therapy. https://app.cochat.ai/papers/10.1158/1535-7163.mct-09-1117
The paper
Moulder, S., Yan, K., Huang, F., Hess, K. R., Liedtke, C., Lin, F., Hatzis, C., Hortobagyi, G. N., Symmans, W. F., & Pusztai, L. (2010). Development of Candidate Genomic Markers to Select Breast Cancer Patients for Dasatinib Therapy. Molecular Cancer Therapeutics. https://doi.org/10.1158/1535-7163.mct-09-1117

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.